News For OPTR From The Last 14 Days Check below for free stories on OPTR the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 5, 2010
|
| 09:44 EDT |  | OPTR |
| theflyonthewall.com: | Gappers report: Bullish gaps | | This is a list of stocks making unusual moves on the open versus the prior day close. Gapping stocks often have excessive movements during the day and in the days thereafter. We use 5% for filter criteria and scanned for stocks that traded above $10 the prior day. GAPPING UP: TCI 5.56%, CTCT 5.86%, TSN 5.93%, HAIN 6.61%, RMD 7.99%, PKI 8.48%, LMNX 8.85%, ALKS 10.36%, FARO 10.86%, SFLY 12.30%, LRN 12.66%, OPTR 13.83%, ARG 43.92%. :theflyonthewall.com |
| | 09:27 EDT | | OPTR |
|
|
February 4, 2010
|
| 16:31 EDT |  | OPTR |
| theflyonthewall.com: | Optimer Pharm announces results from second Fidaxomicin Phase 3 study | | Optimer Pharmaceuticals announced positive top-line results from the second of two pivotal Phase 3 trials evaluating the safety and efficacy of fidaxomicin, or OPT-80, in patients with Clostridium difficile Infection. The trial met the primary endpoint of non-inferiority with 91.7% of patients treated with fidaxomicin achieving clinical cure vs. 90.6% for Vancocin, the only FDA-approved therapy for CDI. Importantly, fidaxomicin also had significantly lower recurrence rates and higher global cure rates compared to Vancocin. :theflyonthewall.com |
|
|
|
Subscribe for More Information